429 related articles for article (PubMed ID: 29949454)
1. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
2. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
3. Association of Pregnancy and Insurance Status With Treatment Access for Opioid Use Disorder.
Patrick SW; Richards MR; Dupont WD; McNeer E; Buntin MB; Martin PR; Davis MM; Davis CS; Hartmann KE; Leech AA; Lovell KS; Stein BD; Cooper WO
JAMA Netw Open; 2020 Aug; 3(8):e2013456. PubMed ID: 32797175
[TBL] [Abstract][Full Text] [Related]
4. Barriers to accessing opioid agonist therapy in pregnancy.
Bedrick BS; O'Donnell C; Marx CM; Friedman H; Carter EB; Stout MJ; Kelly JC
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100225. PubMed ID: 33345932
[TBL] [Abstract][Full Text] [Related]
5. Treatment access for opioid use disorder among women with medicaid in Florida.
Elmore AL; Patrick SW; McNeer E; Fryer K; Reid CN; Sappenfield WM; Mehra S; Salemi JL; Marshall J
Drug Alcohol Depend; 2023 May; 246():109854. PubMed ID: 37001322
[TBL] [Abstract][Full Text] [Related]
6. Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
Martin PR; Finlayson AJ
Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
9. Reproductive-Age Women's Experience of Accessing Treatment for Opioid Use Disorder: "We Don't Do That Here".
Phillippi JC; Schulte R; Bonnet K; Schlundt DD; Cooper WO; Martin PR; Kozhimannil KB; Patrick SW
Womens Health Issues; 2021; 31(5):455-461. PubMed ID: 34090780
[TBL] [Abstract][Full Text] [Related]
10. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
[TBL] [Abstract][Full Text] [Related]
12. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
[TBL] [Abstract][Full Text] [Related]
13. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
14. Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
Hollander MAG; Jarlenski MP; Donohue JM; Cole ES; Kelley D; Krans EE
Am J Obstet Gynecol; 2019 May; 220(5):502-503. PubMed ID: 30703340
[No Abstract] [Full Text] [Related]
15. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
16. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
17. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
Abraham AJ; Harris SJ; Yarbrough CR
J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Buprenorphine Providers Requiring Cash Payment From Insured Women Seeking Opioid Use Disorder Treatment.
Richards MR; Leech AA; Stein BD; Buntin MB; Patrick SW
Med Care; 2023 Jun; 61(6):377-383. PubMed ID: 37083603
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
Rhee TG; Rosenheck RA
Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
